What Fabric Genomics (formerly Omicia) does

Fabric Genomics, founded in 2009 and headquartered in Oakland, California, is a software and clinical services company that provides AI-powered genomic interpretation for next-generation sequencing (NGS) data. It serves clinical laboratories, children's hospitals, large health systems, and country-level population genomics programs, with primary use cases centered on rare disease diagnosis, rapid whole-genome sequencing for NICU/PICU patients, hereditary cancer and cardiac panel interpretation, and newborn screening. Since May 2025, Fabric has operated as a wholly-owned subsidiary of GeneDx Holdings Corp., following an acquisition valued at up to $51 million (approximately $33.2 million in upfront cash), nearly all of which was subsequently written off as an impairment loss.

The company's core technology is the Fabric Enterprise platform, a cloud-based turnkey system that ingests raw FASTQ data or variant calls and produces clinical reports for panels, whole-exome sequencing (WES), and whole-genome sequencing (WGS). Interpretation is powered by a portfolio of proprietary AI algorithms: VAAST (probabilistic gene burden ranking, published 2011), Phevor (phenotype-driven re-ranking using Human Phenotype Ontology, published 2014), VVP (ultrafast variant prioritization, 2018), Truploidy (consanguinity and penetrance adjustment), ACE (automated ACMG variant classification, validated across 50,000+ variants), and GEM (Genome Explanation Model, the flagship WGS/WES interpretation engine, launched 2020 and validated in Genome Medicine in 2021). Reported performance metrics include 98% of causal variants ranked in the top five candidates, 90% ranked first or second, average clinical review time of 15 minutes per genome, and diagnostic yields up to 50% versus an industry baseline of 25–30%.

Fabric's business model combines a SaaS subscription (Fabric Enterprise, sold via prepaid annual credit balances against sample/analysis usage), usage-based per-sample pricing (notably a $1,000 sample-to-report clinical WGS offering through a Broad Clinical Labs partnership), and CLIA/CAP-accredited clinical interpretation services delivered by a network of ABMGG board-certified professionals. Go-to-market is enterprise-led, with direct sales to large hospital systems and clinical laboratories supplemented by channel partnerships with genomic testing labs (e.g., Broad, Oxford Nanopore, DNAnexus, PlumCare RWE, Galatea Bio). The company maintains HIPAA, ISO 27001, FDA 21 CFR Part 11, CLIA, and CAP compliance.

Name

Fabric Genomics (formerly Omicia)

Legal name

Fabric Genomics, Inc.

Website

https://fabricgenomics.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Fabric Genomics, a GeneDx subsidiary, provides AI-powered genomic interpretation software for clinical labs, children's hospitals, and health systems. Its Fabric Enterprise platform uses proprietary algorithms (GEM, ACE, VAAST) to automate NGS analysis, variant classification, and clinical reporting.

Ownership category

akta.pro rank

Headquarters

HQ city

Oakland

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Software Subscription (Fabric Enterprise): SaaS subscription model for access to Fabric Enterprise platform. Prepaid balance model with annual service periods. Customers purchase prepaid credits against sample/analysis usage.
2. Clinical Interpretation Services: CLIA and CAP accredited clinical interpretation and sign-out services using network of ABMGG board-certified professionals. Supports labs ramping up staffing or for long-term interpretation needs.
3. Per-Sample Pricing: Per-sample pricing model for clinical WGS, such as the $1,000 per sample offering with Broad Clinical Labs partnership.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Fabric Genomics sells an AI-powered, cloud-based genomic interpretation platform (Fabric Enterprise) that performs NGS secondary analysis, ACMG-compliant variant classification, and clinical reporting for hereditary panels, WES, and WGS. Standalone AI engines GEM and ACE automate disease-gene ranking and ACMG classification; the company also offers CLIA/CAP-accredited clinical interpretation and sign-out services and per-sample clinical WGS through partner laboratories.

Product overview

Fabric Genomics (a GeneDx company) offers Fabric Enterprise, a turnkey scalable platform for NGS analysis, interpretation, and clinical reporting powered by proprietary AI. The platform consists of the Fabric Enterprise core platform, the Fabric GEM WGS/WES AI interpretation engine, and the Fabric ACE ACMG classification engine for hereditary panels — all delivering structured-data outputs (VCF, FASTQ, clinical reports). Supporting products include Rapid Long Read WGS (ONT partnership), Fabric Clinical Services (CLIA/CAP accredited), and foundational algorithms VAAST, Phevor, VVP, and Truploidy. The portfolio covers rare disease diagnosis, NICU/PICU rapid WGS, newborn screening, hereditary cancer/cardiac panels, and population genomics programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Fabric Enterprise Platform Turnkey, cloud-based platform for next-generation sequencing secondary analysis, interpretation, and clinical reporting, supporting hereditary panels, whole-exome sequencing (WES), and whole-genome sequencing (WGS) from FASTQ data or variant calls. It includes LIMS/EMR integration, configurable SOP-based workflows, and HIPAA, ISO 27001, and FDA 21 CFR Part 11 compliance. Used by hospital systems, children's hospitals, commercial clinical laboratories, and country genome programs.
• Fabric GEM (Genome Explanation Model) Fabric's AI-powered WGS/WES interpretation engine that uses probabilistic modeling to integrate clinical and genomic evidence (inheritance mode, penetrance, sequence quality, phenotype, consanguinity, ancestry, loss of function) and generate Bayes factor scores for disease-causing candidate ranking. Achieves 90% of causal variants ranked as 1st-2nd candidate and 98% in the top 5, reducing clinical review to about 15 minutes per case. Used by clinical labs and hospitals for rare disease diagnosis.
• Fabric ACE (Artificial Intelligence Classification Engine) Automated ACMG variant classification engine for hereditary disease panels, validated across more than 50,000 variants with 100% match to ClinVar classifications and available for over 4,000 genes in commonly used genetic testing panels. Targeted at clinical laboratories running hereditary cancer, cardiovascular, and reproductive health NGS panels.
• Fabric Clinical Interpretation Services CLIA- and CAP-accredited clinical interpretation and sign-out service staffed by ABMGG board-certified clinical geneticists and variant scientists, covering assay design, validation, interpretation, and reporting. Supports laboratories ramping up staffing or with long-term interpretation needs.
• Rapid Long Read WGS (Oxford Nanopore Partnership) Sample-to-report rapid whole-genome sequencing solution developed in partnership with Oxford Nanopore Technologies, with Fabric's GEM AI engine parameterized for nanopore long-read sequencing. Optimized on more than 100 genomes to maximize accuracy and reduce false positives for structural variants; targeted at NICU/PICU pediatric time-critical settings.

Quantifiable outcome

• 98% of causal variants ranked in top 5 candidates
• +5 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability4 records

Feature7 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Galatea BiominorStrategic or Co-development Partner · 23 June 2025Strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases.
• Intermountain Children's Health / Broad Clinical LabscoreStrategic or Co-development Partner · 13 March 2024Partnership to analyze whole genomes of children sequenced by Broad Clinical Labs to help speed diagnosis of genetic diseases at Intermountain Primary Children's Hospital.
• PlumCare RWEcoreStrategic or Co-development Partner · 7 December 2023Strategic partnership to integrate Fabric AI platform with PlumCare's FirstSteps newborn genome screening program in Greece. Goal to screen every newborn in Greece by whole genome sequencing within five years. Fabric GEM AI algorithm adapted into FirstSteps clinical support tool.
• Oxford Nanopore Technologies (ONT)coreStrategic or Co-development Partner · 31 October 2023Collaboration to develop scalable software solution for end-to-end analysis and clinical reporting of nanopore long-read sequencing data. Initial focus on pediatric and NICU applications. GEM AI engine powers candidate scoring and prioritization.
• Broad InstitutecoreStrategic or Co-development Partner · 11 April 2023Launched $1,000 sample-to-report clinical whole genome sequencing service. Partnership enables competitive pricing with cost transparency while offering better analytical capabilities.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• QIAGEN Digital Insights (formerly QIAact, OmicSoft): QIAGEN's clinical genomics interpretation business provides AI-driven variant analysis and clinical reporting for hereditary disease, oncology, and rare disease — directly competing with Fabric Enterprise in hospital and lab workflows.
• SOPHiA Genetics: Cloud-based AI platform for genomic and multimodal clinical data analysis used by hospitals and labs worldwide for rare disease and oncology interpretation. Closely comparable SaaS business model and customer base.
• Congenica: Clinical genomic interpretation platform used by NHS England and other health systems for rare disease diagnosis. Direct competitor in the clinical genomics interpretation space with similar hospital/lab GTM.
• DNAnexus: Cloud-based genomics data analysis and collaboration platform used by clinical labs and pharma. Although Fabric partners with DNAnexus, both compete for the clinical genomics workflow layer with overlapping LIMS/EMR integration capabilities.
• BC Platforms: Provides genomic data management and clinical interpretation tools for hospital systems and country genome programs (including collaborations with Genomics England). Comparable clinical genomics interpretation offering and similar enterprise health system customers.
• Golden Helix: Genomic analysis software for clinical and research workflows including variant annotation, interpretation, and clinical reporting. Comparable in NGS interpretation functionality and customer profile of clinical labs and hospital systems.

Broad incumbents

• Illumina DRAGEN and Connected Software: Illumina offers DRAGEN secondary analysis plus the PierianDx-acquired clinical interpretation platform, embedding it as part of a broader sequencing hardware and software stack. Comparable functionality with deeper distribution via sequencer placements.
• Verily (Alphabet): Alphabet's life sciences arm operates precision medicine initiatives including large-scale genomic data platforms. Comparable AI/ML application to clinical genomics with substantially larger resources and broader healthcare ambitions.

Emerging players

• Tempus Labs: AI-driven precision medicine company applying machine learning to clinical and molecular data, including NGS interpretation in oncology and increasingly rare disease. Comparable technology stack and clinical interpretation focus, though Tempus is primarily oncology-led.
• Arima Genomics: Emerging player in 3D genomics and clinical interpretation with overlap in NGS-based rare disease workflows. Comparable in genomics interpretation though smaller and more research-oriented than Fabric's commercial clinical focus.

Market position

Strengths5 records

Weaknesses6 records

Competitive moat5 records

Customer concentration

• Xx.com/FabricGenomics
• LinkedInlinkedin.com/company/fabric-genomics

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fabric Genomics (formerly Omicia)